Loading clinical trials...
Loading clinical trials...
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in th...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Catalyst Pharmaceuticals, Inc.
Collaborators
NCT02455479 · Cocaine Dependence
NCT06125054 · Cocaine Use Disorder, Cocaine Dependence
NCT06189690 · Cocaine Dependence
NCT05974202 · Cocaine Use, Cocaine Dependence, and more
NCT04907357 · Cocaine Use Disorder, Methamphetamine Abuse, and more
Matrix Institute on Addictions
Los Angeles, California
Friends Research Institute
Torrance, California
VA Medical Center
Denver, Colorado
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions